BioSpace News Archive

ANGLE plc is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium.

Thermosome today announced the appointment of Dr. Frank Hermann, MD, as Chief Medical Officer (CMO) and the expansion of its Clinical Advisory Board with the addition of Prof. Alessandro Gronchi, MD.

Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has strengthened its commercial organization with the promotion of Glenn E. Pauly to Chief Commercial Officer and the appointments of Dina Lynch to Vice President of Market Access, and Nate Greene to Vice President of Brand Marketing.

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS).

NVIGEN, a leader in providing modern nanoparticle health care solutions, is poised to unveil its groundbreaking technology, NVIGEN X®-Precision Medicine Biomarker Profiling, at the San Antonio Breast Cancer Symposium from December 5 to 9.

Hoth Therapeutics, Inc. today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP).

Geneoscopy, Inc. and Adiso Therapeutics, Inc. today announced a strategic collaboration to further treatment options available for patients with inflammatory bowel disease (IBD).

AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience.

Mainz Biomed N.V. announced today groundbreaking topline results from its eAArly DETECT U.S. clinical study, a multi-center feasibility study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into a next generation version of ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories.